Lilly posts pro forma on ImClone deal

Eli Lilly expects its combination with ImClone to deliver $15.5 billion in revenues for the nine months ended Sept. 30 and a combined EPS of 1.21, which because of acquisition costs and interest expenses is some 20 cents per share less than Lilly would have produced on its own. Report

Suggested Articles

Mobile has become universal, accessible, and multi-generational. It’s time for life science brands to revolutionize how they’re telling their story.

Former Retrophin CEO was hoping for a SCOTUS hail mary to escape his seven-year fraud sentences Turns out the court was interest in hearing his plea.

A new investigation shines light on how Purdue pushed back on negative coverage of opioids, placed opioid-friendly experts in think tanks and more.